US-based firm Eco Petroleum Solutions has completed the acquisition of drug development company Immunotech Laboratories in a share exchange transaction.
Immunotech Laboratories specialises in the commercialisation of its proprietary proteins to treat patients affected with debilitating infectious diseases.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Under the deal, the company is committed to develop drugs to ensure the better health of human beings and for the realisation of shareholder value for the existing shareholder groups of the two companies.
The major Immunotech compound ITV-1 is a suspension of inactivated pepsin fragment (IPF), which, according to studies conducted, is believed to be effective in the treatment of HIV.
IPF is the active drug substance of ITV-1 and a purified extract of porcine pepsin.
ITV-1 has revealed capability of modulating the immune system, as well as successfully completed its Phase I, II and III clinical trials in Sophia, Bulgaria, through Immunotech Laboratories BG – Europe, a subsidiary of the acquired organisation.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe final report of the Phase III trial was performed on a test group of salvage patients suffering from HIV / AIDS, and showed that improvement in the immune indices in the absolute number of Ly, CD3 T, CD4 T, CD8 T, B Ly, NK and in the percentage of CD3 T, CD4 T, CD8 T, B Ly, NK and of the index CD4/CD8 decreased in the viral load.
It also demonstrated a good treatment effect on opportunistic infections, compatibility with all of the other modern antiretroviral drugs and exceptional tolerance in all patients with a complete lack of any major side effects.
The validation of treatment manufacturing produced by a US contract manufacturer is currently in process.
